Towards targeting PD-1/PD-L1 axis in breast cancer, pre-clinical data
暂无分享,去创建一个
G. Höfler | G. Zlabinger | P. Steinberger | T. Chernova | Yoshiko Iwai | U. Korthäuer | A. Long | E. Guthann | A. Szekeres | Karen Bourque | K. Bourque
[1] A. Qattan,et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. , 2006, Neoplasia.
[2] O. Majdic,et al. B7-H1 (Programmed Death-1 Ligand) on Dendritic Cells Is Involved in the Induction and Maintenance of T Cell Anergy 1 , 2003, The Journal of Immunology.
[3] G. Freeman,et al. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.